Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

BACKGROUND: Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipients have been excluded from clinical trials owing to concerns about alloimmunity,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Abdel-Wahab, Noha, Safa, Houssein, Abudayyeh, Ala, Johnson, Daniel H., Trinh, Van Anh, Zobniw, Chrystia M., Lin, Heather, Wong, Michael K., Abdelrahim, Maen, Gaber, A. Osama, Suarez-Almazor, Maria E., Diab, Adi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469201/
https://ncbi.nlm.nih.gov/pubmed/30992053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0585-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados